fashion -WSS

fashion

author：knowledge 2025-10-02 22:15:28 - browse：6

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： UnitedHealth CEO's Medicaid comments send insurer stocks diving

entertainment

WSS

Weighted lottery helped low

Congress needs to close a vaccine

NIH nominee Bertagnolli will get October confirmation hearing

Stopping antidepressants leads to symptoms for 1 in 6 patients

Amazon on where the company's health care bets are headed next

Elevance PBM president out as customers face prescription chaos

explore

fashion

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

AstraZeneca chief proposes a novel edit to the drug pricing bill

Affirmative action in medical school literally saved lives

Ethical issues complicate the benefits of medical crowdfunding

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

What drug price negotiations mean for Medicare Part D

Sports medicine is finally prioritizing gender equality

House transparency, PBM reform bill gains bipartisan support

Affirmative action in medical school literally saved lives

Finland to offer bird flu vaccine to select groups of people, a possible global first

entertainment

Stem cell treatment guidelines are released by FDA

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Data don't support strong claims for Covid

FTC loses bid to block Novant's North Carolina hospital merger

A rare thyroid diagnosis led to unexpected, all

Illumina board agrees to spin off Grail, as divestment plans proceed

entertainment

knowledge

leisure time

entertainment